News
News
Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case
Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case
Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA Bioresorbable Scaffold for Peripheral Vascular Disease
Sunnyvale, CA — October 20, 2016 – Akesys Medical, a drug-device company focused on pioneering innovative solutions for peripheral artery disease, has announced their first clinical
Elixir Medical Announces Excellent, 3-Year Clinical and Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
Golden Tube Visualization, Low MACE and Lumen Gain Sustained Long-Term Sunnyvale, Calif. – October 15, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical
Elixir Medical Announces Successful Live Case Transmission of DESolve Cx at TCT
Sunnyvale, Calif. – October 13, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that on Mon., October 12,
Elixir Medical Receives 2015 Innovator of the Year Award from EK-UNICO
Sunnyvale, Calif. – August 17, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received the
Elixir Medical Announces Excellent, 3-Year Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
Successful Live Case of DESolve® 100 implantation at Elixir Symposium at EuroPCR 2015 Sunnyvale, Calif. – May 20, 2015 — Elixir Medical Corporation, a developer of products that
PMN 1714 Rev A